Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Dolutegravir (S/GSK1349572) is a once-daily HIV integrase inhibitor with potent antiviral
activity and a favourable safety profile. We compared dolutegravir with HIV integrase
inhibitor raltegravir, as initial treatment for adults with HIV-1.